Insight Molecular Diagnostics Inc. Strategic Asset Allocation Index
Insight Molecular Diagnostics Inc. strategic asset allocation index. Insight Molecular Diagnostics Inc. (IMDX) has a Strategic Asset Allocation Index of 0.0% as of December 2021. Strategic assets (PP&E of $- plus long-term investments of $0.00) total $0.00, measured against net assets of $65.22 Million. A higher index reflects capital-intensive or investment-heavy strategies where strategic assets dominate the equity base. Check tangible net worth ratio of Insight Molecular Diagnostics Inc. to evaluate the tangible quality of the company's equity base.
SAAI
Strategic Assets
PP&E
Net Assets
Strategic Asset Allocation Index of Insight Molecular Diagnostics Inc. (2021–2021)
Strategic asset allocation index of Insight Molecular Diagnostics Inc. from 2021 to 2021. This chart shows how Insight Molecular Diagnostics Inc.'s Strategic Asset Allocation Index has evolved across 1 annual periods from 2021 to 2021. As of December 2021, the index stands at 0.0%, representing strategic assets of $0.00 against net assets of $65.22 Million USD.
Insight Molecular Diagnostics Inc. Strategic Asset Allocation Index by Year (2021–2021)
Insight Molecular Diagnostics Inc. strategic asset allocation index by year from 2021 to 2021. The table below presents the year-by-year Strategic Asset Allocation Index for Insight Molecular Diagnostics Inc. from 2021 to 2021, covering 1 annual filings. Each row shows PP&E, long-term investments, strategic assets combined, net assets, the index percentage, and the change in percentage points compared to the prior year. For live market cap and overall valuation, see IMDX company net worth.
| Year | SAAI | Strategic Assets (USD) | PP&E | LT Investments | Net Assets | Change (pp) |
|---|---|---|---|---|---|---|
| 2021 | 0.0% | $0.00 | $- | $0.00 | $65.22 Million | — |